Valuation dashboard for Travere Therapeutics, Inc. (TVTX) with P/E N/A, P/B 197.35, EV/EBITDA 916.44 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II).
Analysis Summary
Travere Therapeutics, Inc. reported revenue of $490.7M in the most recent fiscal year, growing at a 5-year CAGR of 19.9%.
Trailing-twelve-month margins: gross margin 94.4%, operating margin -6.8%, net margin -7.4%.
At $50.84 (closing price, October 28, 2026), TVTX has negative trailing earnings (P/E not meaningful) and an ROE of -55.79%. Market capitalisation stands at $4.8B.
Balance sheet quality for TVTX: current ratio of 2.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 197.35 |
| EV / EBITDA | 916.44 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-234.31 |
| vs Current Price | -560.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | $4.8B | 197.35 | -55.8% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.3B | 30.83 | 6.60 | 23.3% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| MRNA | Moderna, Inc. | $85.5B | 11.99 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $83.7B | 20.12 | 2.62 | 13.8% |
| ARGX | argenx SE | $56.1B | 31.90 | 6.50 | 21.7% |
| 0QNO.L | Lonza Group AG | $43.8B | 5.43 | -1.3% |
Price
| Price | $50.84 (closing price, October 28, 2026) |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -55.79% |
| Return on Invested Capital | -6.19% |
| Return on Assets | -5.44% |
| Gross Margin | 94.41% |
| Operating Margin | -6.84% |
| Net Margin | -7.35% |
Related companies: VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of TVTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks